Fluid Pharma is pleased to announce that TAT-FIT™ will be exhibited at three key research and laboratory animal science events this autumn, providing opportunities to connect with researchers and share how our technology can support the refinement of oral dosing in preclinical research.

TAT-FIT™ is Fluid Pharma’s, our innovative formulation of taste masked tamoxifen micropellets, designed to support ethical, non-invasive oral dosing in transgenic mouse studies using Fluid Pharma’s MicroCoat® technology.

The first event will be NMGN Science Days 2026, taking place in York on 22–23 September. Fluid Pharma is also pleased to be a sponsor of this year’s two-day event, which brings together the mouse genetics research community for a programme of research presentations, poster sessions and networking

Following NMGN Science Days, Fluid Pharma will exhibit TAT-FIT™ at Oxford 3Rs Day at the University of Oxford on 7 October. The event provides another opportunity to share TAT-FIT™ and its role in supporting the refinement of oral dosing practices with the research community.

Our final conference of the autumn will be the LASA Annual Conference 2026, taking place from 16–18 November. Following our attendance at LASA in 2025, we are looking forward to returning this year and once again showcasing TAT-FIT™ to researchers and laboratory animal science professionals.

These three events provide valuable opportunities for Fluid Pharma to demonstrate TAT-FIT™, and connect with those working to advance research practices and animal welfare.

If you are attending any of these events, we look forward to meeting you and sharing more about TAT-FIT™.